QL335 / Qilu Pharma, QLSF Biotherapeutics - LARVOL DELTA

QL335, a novel T cell engager with enhanced safety profile targeting MSS colorectal cancer (AACR 2024) - "Importantly, QL335 was well tolerated in cynomolgus monkeys dosed up to 50 mg/kg, supporting the enhanced safety profile by design of this therapeutic candidate. QL335 is currently being evaluated in a phase 1 clinical trial."

Clinical • IO biomarker • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • LY6G6D